Effect of Weight Reduction on Immunity
Primary Purpose
Lymphocytes, Weight Loss, Viral Diseases
Status
Completed
Phase
Phase 3
Locations
Study Type
Interventional
Intervention
weight loss program
Sponsored by
About this trial
This is an interventional other trial for Lymphocytes
Eligibility Criteria
Inclusion Criteria:
- BMI >=30
- female
- healthy
- no smoking
- not lactating
- not pregnant
- no medication use
Exclusion Criteria:
- pregnancy
- any disease
- any medication use
- iron and zinc deficiency
- any supplement use
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Other
No Intervention
Arm Label
experimental
control
Arm Description
This group underwent a weight loss program
This group underwent adlibitum diet + physical activity
Outcomes
Primary Outcome Measures
lymphocyte subgroups
TCD3. TCD4. TCD8. BCD19. NKCs CD16/56 (Cells/microliter) by flowcytometry
Secondary Outcome Measures
Body Mass Index
(Kg/m^2) by equation
Biomarkers
ZN, Iron (microgram/deciliter) by biochemical assessment
Systolic blood pressure
(mmHg) by manometer
diastolic blood pressure
(mmHg) by manometer
Weight
(Kg) by Bioelectric impedance analyser
Fat Mass
(Kg) by Bioelectric impedance analyser
Fat Free Mass
(Kg) by Bioelectric impedance analyser
Trunk Fat
(Kg) by Bioelectric impedance analyser
Waist circumference
(cm) by meter tape
Full Information
NCT ID
NCT03336086
First Posted
September 17, 2017
Last Updated
November 7, 2017
Sponsor
Shiraz University of Medical Sciences
Collaborators
Mashhad University of Medical Sciences
1. Study Identification
Unique Protocol Identification Number
NCT03336086
Brief Title
Effect of Weight Reduction on Immunity
Official Title
Reduction of Natural Killer Cell (CD16/56) and T-lymphocyte (CD3) Subset Counts After a Weight Loss Program Using Anti-obesity Drugs in Obese Women: a Non-randomized Controlled Trial
Study Type
Interventional
2. Study Status
Record Verification Date
October 2017
Overall Recruitment Status
Completed
Study Start Date
March 20, 2012 (Actual)
Primary Completion Date
November 30, 2012 (Actual)
Study Completion Date
December 25, 2012 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Shiraz University of Medical Sciences
Collaborators
Mashhad University of Medical Sciences
4. Oversight
Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
Yes
Product Manufactured in and Exported from the U.S.
No
5. Study Description
Brief Summary
This study included two groups of premenopausal healthy obese women. Experimental group underwent a weight loss program involved a low calorie diet plus anti-obesity drugs and moderate physical activity and control group underwent an ad libitum diet. At baseline and after a 10-15% weight loss lymphocyte subgroups were analyzed and compared between two group.
Detailed Description
TCD3 and NKC CD16/56 were decreased significantly. Hence this weight loss program impaired viral immunity
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Lymphocytes, Weight Loss, Viral Diseases, Immunity, Anti-obesity Agents
7. Study Design
Primary Purpose
Other
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Allocation
Non-Randomized
Enrollment
29 (Actual)
8. Arms, Groups, and Interventions
Arm Title
experimental
Arm Type
Other
Arm Description
This group underwent a weight loss program
Arm Title
control
Arm Type
No Intervention
Arm Description
This group underwent adlibitum diet + physical activity
Intervention Type
Combination Product
Intervention Name(s)
weight loss program
Other Intervention Name(s)
experimental
Intervention Description
A low calorie diet+ Orlistat+ Soluble Fiber+ Physical activity
Primary Outcome Measure Information:
Title
lymphocyte subgroups
Description
TCD3. TCD4. TCD8. BCD19. NKCs CD16/56 (Cells/microliter) by flowcytometry
Time Frame
6 months
Secondary Outcome Measure Information:
Title
Body Mass Index
Description
(Kg/m^2) by equation
Time Frame
6 months
Title
Biomarkers
Description
ZN, Iron (microgram/deciliter) by biochemical assessment
Time Frame
6 months
Title
Systolic blood pressure
Description
(mmHg) by manometer
Time Frame
6 months
Title
diastolic blood pressure
Description
(mmHg) by manometer
Time Frame
6 months
Title
Weight
Description
(Kg) by Bioelectric impedance analyser
Time Frame
6 months
Title
Fat Mass
Description
(Kg) by Bioelectric impedance analyser
Time Frame
6 months
Title
Fat Free Mass
Description
(Kg) by Bioelectric impedance analyser
Time Frame
6 months
Title
Trunk Fat
Description
(Kg) by Bioelectric impedance analyser
Time Frame
6 months
Title
Waist circumference
Description
(cm) by meter tape
Time Frame
6 months
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
45 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
BMI >=30
female
healthy
no smoking
not lactating
not pregnant
no medication use
Exclusion Criteria:
pregnancy
any disease
any medication use
iron and zinc deficiency
any supplement use
12. IPD Sharing Statement
Learn more about this trial
Effect of Weight Reduction on Immunity
We'll reach out to this number within 24 hrs